Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 32, Issue 10, 2017, Pages 1655-1665

  Barutta, Federica ^a   Grimaldi, Serena ^a   Gambino, Roberto ^a   Vemuri, Kiran ^b   Makriyannis, Alexandros ^b   Annaratone, Laura ^a   Di Marzo, Vincenzo ^c   Bruno, Graziella ^a   Gruden, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NORTHEASTERN UNIVERSITY   (United States)

^c CNR   (Italy)

Author keywords

albuminuria; CB1R antagonist; CB2R agonist; diabetic nephropathy; endocannabinoid system

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; ALBUMIN; AM 6545; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; NEPHRIN; UNCLASSIFIED DRUG; AM6545; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL DIABETIC NEPHROPATHY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIMIT OF QUANTITATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEPLETION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPLICATION; DIABETIC NEPHROPATHY; DRUG COMBINATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; LEUKOCYTE ACTIVATION; METABOLISM; PRECLINICAL STUDY;

ALBUMINURIA; ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; NEUTROPHIL ACTIVATION; PODOCYTES; PYRAZOLES;

EID: 85030725936     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx010     Document Type: Article

References (38)

1. Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol 2013; 9: 713-723
2. Gruden G, Barutta F, Kunos G et al. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol 2016; 173: 1116-1127
3. Silvestri C, DiMarzo V. The endocannabinoid systemin energy homeostasis and the etiopathology of metabolic disorders. CellMetab 2013; 17: 475-490
4. Barutta F, Corbelli A, Mastrocola R et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010; 59: 1046-1054
5. Barutta F, Piscitelli F, Pinach S et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011; 60: 2386-2396
6. Barutta F, Grimaldi S, Franco I et al. Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. Kidney Int 2014; 86: 979-990
7. Janiak P, Poirier B, Bidouard JP et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 2007; 72: 1345-1357
8. Lim JC, Lim SK, Park MJ et al. Cannabinoid receptor 1 mediates high glucose-induced apoptosis via endoplasmic reticulum stress in primary cultured rat mesangial cells. Am J Physiol Renal Physiol 2011; 301: F179-F188
9. Nam DH, Lee MH, Kim JE et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/ db mice. Endocrinology 2012; 153: 1387-1396
10. Russell JC, Kelly SE, Diane A et al. Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. Am J Physiol Gastrointest Liver Physiol 2010; 299: G507-G516
11. Zoja C, Locatelli M, Corna D et al. Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy. Nephron 2016; 132: 59-69
12. Jourdan T, Szanda G, Rosenberg AZ et al. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci USA 2014; 111: E5420-E5428
13. Lecru L, Desterke C, Grassin-Delyle S et al. Cannabinoid receptor 1 is a majormediator of renal fibrosis. Kidney Int 2015; 88: 72-84
14. Tam J, Vemuri VK, Liu J et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-2966
15. Tam J, Cinar R, Liu J, Godlewski G et al. Peripheral cannabinoid-1 receptor inverse agonist reduces obesity by reversing leptin resistance. Cell Metab 2012; 16: 167-179
16. Callen L, Moreno E, Barroso-Chinea P et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 2012; 287: 20851-20865
17. Börner C, SmidaM, Höllt V et al. Cannabinoid receptor type 1-and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem 2009; 284: 35450-35460
18. Cluny NL, Vemuri VK, Chambers AP et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010; 161: 629-642
19. Ibrahim MM, Deng H, Zvonok A et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100: 10529-10533
20. Dunn SR, Qi Z, Bottinger EP et al. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004; 65: 1959-1967
21. Saleem MA, O'Hare MJ, Reiser J et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638
22. Kigerl K, Gensel J, Ankeny D et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009; 29: 13435-13444
23. Taniguchi K, Hikiji H, Okinaga T et al. Essential role of lysophosphatidylcholine acyltransferase 3 in the induction of macrophage polarization in PMA-treated U937 cells. J Cell Biochem 2015; 116: 2840-2848
24. Giunti S, Pinach S, Arnaldi L et al. The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int 2006; 69: 856-863
25. Doublier S, Ruotsalainen V, Salvidio G et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158: 1723-1731
26. Barutta F, Bruno G, Grimaldi S et al. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine 2015; 48: 730-742
27. Giunti S, Barutta F, Cavallo Perin P et al. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vasc Pharmacol 2010; 8: 849-860
28. Giunti S, Tesch GH, Pinach S et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008; 51: 198-207
29. Biswas SK, Chittezhath M, Shalova IN et al. Macrophage polarization and plasticity in health and disease. Immunol Res 2012; 53: 11-24
30. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604
31. Mantovani A, Biswas SK, Galdiero MR et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229: 176-185
32. Wan J, Benkdane M, Teixeira-Clerc F et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014; 59: 130-142
33. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev 2005; 1: 27-40
34. Schaich CL, Shaltout HA, Brosnihan KB et al. Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats. Physiol Rep 2014; 2: 1-10
35. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634
36. Kangas BD, Delatte MS, Vemuri VK et al. Cannabinoid discrimination and antagonism by CB1 neutral and inverse agonist antagonists. J Pharmacol Exp Ther 2013; 344: 561-567
37. Shikata K, Makino H. Microinflammation in the pathogenesis of diabetic nephropathy. J Diabetes Investig 2013; 4: 142-149
38. BuraczynskaM,Wacinski P, Zukowski P et al. Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes. J Diabetes Complicat 2014; 28: 35-39